P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)

Abstract

cachexia. The specific assessments are: Patient generated subjective global assessment (PG-SGA) G8 EORTC QLQC30 EORTC LC13 Performance status Hand grip strength Spirometry Psoas muscle assessment from diagnostic cross sectional imaging Charlson Co-morbidity Index Inclusion criteria are: Patients >18 years old who are able to consent to entry into a clinical trial Biopsy confirmed Advanced NSCLC (stage IIIb and IV). Patient receiving first line systemic palliative anti-cancer treatment. Exclusion criteria are: Inability to consent to treatment Patient declines anti-cancer treatment Result: Section not applicable Conclusion: It is anticipated that the results will clarify if a nutritional screening tool such as the PG-SGA can identify patients at risk of malnutrition prior to starting anti-cancer treatment, as well as highlight those who require dietetic intervention. It is hoped that this research will inform a randomised clinical trial of dietetic counselling in lung cancer.

Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma

“…Eribulin, a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin B and a specific inhibitor of TERT -RNA-dependent RNA polymerase, was used in patients with TERT promoter mutation according to published preclinical data (Takahashi et al 2019 ). Cabozantinib, a small molecule multi-tyrosine kinase inhibitor against vascular endothelial growth factor receptor ( VEGFR ) and MET was used in patients with MET amplification, as it was shown to be effective in the treatment of lung cancer (D’Arcangelo et al 2019 ). The combination of dabrafenib plus trametinib represents standard of care for BRAF-V600E -mutant melanoma and lung cancer patients (Long et al 2015 ; Planchard et al 2017 ) and was applied in case of BRAF-V600E mutation on the basis of several case reports in brain tumors (Johanns et al 2018 ).…”

Meeting an un-MET need: Targeting MET in non-small cell lung cancer

“…More data is required to evaluate the efficacy of cabozantinib in MET-altered NSCLC. Results are awaited in the ongoing phase II trial, CABinMET (Supplemental Table 2) (41).…”

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics

“…53,54 Cabozantinib is another non-selective TKI with reported activity and off-label use in MET-driven NSCLC, currently under investigation in the Italian CABinMET study (NCT03911193) in subjects with tumors harboring METex14 mutations or MET amplification. 55 The phase II VISION study of tepotinib in METex14 skipping NSCLC found an ORR 46% and median DOR 11.1 months. 56 The phase Ib/II INSIGHT study (NCT01982955) found tepotinib plus gefitinib to be superior to platinum-pemetrexed duet chemotherapy (ORR 45% vs 33%) for pretreated EGFR-positive NSCLC, particularly for tumors with MET amplification.…”

“… 53 , 54 Cabozantinib is another non-selective TKI with reported activity and off-label use in MET-driven NSCLC, currently under investigation in the Italian CABinMET study (NCT03911193) in subjects with tumors harboring MET ex14 mutations or MET amplification. 55 …”